(Q43908078)

English

131I-Anti CD20 Radioimmunotherapy of Relapsed or Refractory Non-Hodgkins Lymphoma: A Phase II Clinical Trial of a Nonmyeloablative Dose Regimen of Chimeric Rituximab Radiolabeled in a Hospital

scientific article published on August 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

131I-Anti CD20 Radioimmunotherapy of Relapsed or Refractory Non-Hodgkins Lymphoma: A Phase II Clinical Trial of a Nonmyeloablative Dose Regimen of Chimeric Rituximab Radiolabeled in a Hospital (English)

1 reference

10.1089/108497803322287583

https://api.crossref.org/works/10.1089/108497803322287583

13 March 2024

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

radioimmunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14503945

13 March 2024

1 reference

10.1089/108497803322287583

https://api.crossref.org/works/10.1089/108497803322287583

13 March 2024

1 reference

10.1089/108497803322287583

https://api.crossref.org/works/10.1089/108497803322287583

13 March 2024

author name string

Jan Boucek

3

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

J. Harvey Turner

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14503945

13 March 2024

Andrew A. Martindale

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14503945

13 March 2024

Phillip G. Claringbold

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14503945

13 March 2024

Michael F. Leahy

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14503945

13 March 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14503945

13 March 2024

publication date

1 August 2003

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

full work available at URL

http://www.liebertpub.com/doi/pdf/10.1089/108497803322287583

1 reference

10.1089/108497803322287583

https://api.crossref.org/works/10.1089/108497803322287583

13 March 2024

Cancer Biotherapy and Radiopharmaceuticals

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

513-524

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study

1 reference

https://opencitations.net/index/api/v1/citations/10.1002/CNCR.10307

30 December 2023

A revolution in the treatment of non-Hodgkin's lymphoma

1

1 reference

10.1089/108497803322287583

https://api.crossref.org/works/10.1089/108497803322287583

13 March 2024

Annals of Internal Medicine

2

13

916

author name string

Press OW

publication date

2002

1 reference

10.1089/108497803322287583

https://api.crossref.org/works/10.1089/108497803322287583

13 March 2024

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

4

1 reference

10.1089/108497803322287583

https://api.crossref.org/works/10.1089/108497803322287583

13 March 2024

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

6

1 reference

10.1089/108497803322287583

https://api.crossref.org/works/10.1089/108497803322287583

13 March 2024

Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy

7

1 reference

10.1089/108497803322287583

https://api.crossref.org/works/10.1089/108497803322287583

13 March 2024

Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity

8

1 reference

10.1089/108497803322287583

https://api.crossref.org/works/10.1089/108497803322287583

13 March 2024

Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess

9

1 reference

10.1089/108497803322287583

https://api.crossref.org/works/10.1089/108497803322287583

13 March 2024

The emerging role of radioimmunotherapy in haematological malignancies

12

1 reference

10.1089/108497803322287583

https://api.crossref.org/works/10.1089/108497803322287583

13 March 2024

Biodistribution and kinetics of 131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma

14

1 reference

10.1089/108497803322287583

https://api.crossref.org/works/10.1089/108497803322287583

13 March 2024

Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma

15

1 reference

10.1089/108497803322287583

https://api.crossref.org/works/10.1089/108497803322287583

13 March 2024

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

17

1 reference

10.1089/108497803322287583

https://api.crossref.org/works/10.1089/108497803322287583

13 March 2024

Is high-dose radioimmunotherapy needed in non-Hodgkin's lymphoma? For

19

1 reference

10.1089/108497803322287583

https://api.crossref.org/works/10.1089/108497803322287583

13 March 2024

Identifiers

10.1089/108497803322287583

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43908078&oldid=2106016944"